Acroscell, as the division of Creaitve Bioarray, offering an innovative, time-efficient, cost-effective and comprehensive range of preclinical R&D services specialized in but not limited to cardiovascular & neural system physiological/pathophysiological mechanisms with strong scientific support.
Shirley, USA - July 8, 2019 /MarketersMedia/ —
New York, Jun 30th, 2019 - Acroscell, as the division of Creative Bioarray, offering an innovative, time-efficient, cost-effective and comprehensive range of preclinical R&D services specialized in but not limited to cardiovascular & neural system physiological/pathophysiological mechanisms with strong scientific support. Acroscell recently announces its release of the ion channel screening service to acceleration the development of drug discovery program.
Ion channels are an important therapeutic target for a range of indications, including the heart, central nervous system, immune system, and metabolic diseases. Due to the recent successful development of new screening technologies, the interest of ion channels as drug targets has increased significantly.
With an innovative technology platform, Acroscell has the ability to efficiently service your ion channel drug discovery program. Acroscell can test the ion channel selectivity of your compound, develop new cell lines that express the ion channels of interest in your discovery program or validate existing ion channel expressing cell lines. Meanwhile, Acroscell offers a wide range of ion channel screening assays including more than 80 ion channel targets and more than 200 ion channel analyses. To provide rapid and accurate results for drug discovery, Acroscell provides a broad range of binding or functional assays for ion channel screening assays.
The Kv11.1 channel is a potassium ion channel (also known as the hERG channel) encoded by the human ether-related (hERG) gene and plays a critical role in the repolarization of cardiac action potentials. The hERG inhibition test provides extraordinary sensitivity, much greater than full organ analysis or whole animal analysis. Acroscell uses the most advanced automated QPatch-HT system to deliver higher throughput hERG safety analysis at a lower cost. For small amounts of compounds or compounds identified using QPatch, we can also perform routine whole-cell patch clamp assays to obtain detailed mechanical information. Our GLP level hERG security analysis provides high quality data for registration purposes.
Besides, calcium channels have been recognized as therapeutic targets for the treatment of many diseases. However, calcium channel classes are considered underdeveloped due to the lack of reliable functional cell-based assays for high throughput screening. Acroscell utilizes automatic patch-clamp technology to test compound calcium channel activity using fura-2 AM dye for compound treatment and digital cellular imaging in a single human living cell.
About Acroscell
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Phone: 6316197922
Website: https://www.creative-bioarray.com/acroscell/
Source: MarketersMedia
Release ID: 88891265
